Silence Therapeutics Plc (NASDAQ:SLN) shares are up during Friday's session.
On Thursday, the company highlighted follow-up data from its Phase 1 SANRECO study of divesiran.
SLN Stock Catalyst: SANRECO Phase 1 Follow-Up Data Recent analyses from the Phase 1 SANRECO study show potential improvements in symptoms and quality of life for patients with polycythemia vera (PV).
Additional analyses also showed reductions in phlebotomy use persisted well beyond the final dose.
The ongoing Phase 2 SANRECO study is on track to deliver topline results in August 2026, further supporting the stock's upward movement.
